Lung Cancer Vaccination Study Program: Stimuvax

CORT continues its investigation of a vaccine for prevention of recurrence of Stage III Non-Small Cell Lung Cancer )(NSCLC).  In collaboration with EMD Pharmaceuticals, CORT is conducting a study of Stimuvax, a vaccine for patients who have completed a standard program of chemotherapy and radiation therapy for treatment of unresectable Stage III NSCLC. 

Patients who qualify will randomly receive a placebo or active vaccine treatment for 8 weekly doses, followed by 4 additional doses every 6 weeks.  For information on this study, call 972-566-5588 and ask to speak with a Study Coordinator.  Additional information about CORT and the studies available may be found at www.CORTPA.com

Patients who have unresectable Stage III NSCLC who complete a standard program of chemotherapy and radiation therapy continue to have a very high risk of recurrence.  The purpose of this study is to determine if the vaccination program can effectively reduce that risk. 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s


%d bloggers like this: